Skip to main content

Generics

  • Teva launches new generic Pulmicort Respules dosage strength
    JERUSALEM — Teva on Wednesday announced the U.S. launch of the 1-mg/2-ml dosage strength of its generic Pulmicort Respules (budesonide inhalation suspension). 
     
    With the launch, the company completes its portfolio of Pulmicort Respules generics, having previously launched it in strengths of 0.25/2 ml and 0.5 mg/2 ml. The drug is indicated to control and prevent asthma symptoms in children aged 1 to 8 year. 
     

  • Lupin completes Gavis acquisition
    MUMBAI and BALTIMORE — Lupin announced Wednesday that it had completed its acquisition of Gavis, which includes Gavis Pharmaceuticals and Novel Laboratories, for about $880 million. 
     
    Lupin said the acquisition will grow the company’s footprint in the U.S. generics market and expands its dermatology, controlled substance product and high value and niche generics pipeline. With the acquisition, Lupin also gains its first manufacturing site in the United States — Gavis’ New Jersey manufacturing facility. 

  • Five big ideas for chronic care management

  • CMS plan to boost MTM gains traction in Congress

    “Better care, smarter spending, healthier people.”

  • Demand for generics remains strong, fueling steady growth in market share

    Like a powerful tide that gradually eats away at the foundations of a once-impregnable sea wall, the booming market for generic drugs advances and recedes with the rise and fall in the number of branded drug patent expirations each year. But their long-term growth momentum remains on course, making generics an implacable force chipping away at what’s left of the market domain held by traditionally derived, broadly focused blockbuster drugs.

  • Alvogen to acquire County Line Pharmaceuticals
    PINE BROOK, N.J. — Pharmaceutical company Alvogen announced Monday that it would be acquiring Wis.-based specialty generics company County Line Pharmaceuticals. 
     

  • CVS Health to offer naloxone without prescription in 23 states by month's end
    WOONSOCKET, R.I. - CVS Health announced Monday that it will expand access to the opioid overdose-reversal medication naloxone at the end of March at its CVS Pharmacy locations in eight new states, including: Connecticut, Kentucky, Maryland, North Carolina, New Hampshire, Ohio, Virginia and Vermont.  
     
    Under a physician-approved protocol permitted by the state, CVS Pharmacy will be able to dispense naloxone to patients in these states without the need for an individual prescription.
     

  • Senate approves Medicare 'lock-in' amendment on opioid abuse
    WASHINGTON - The United States Senate approved an amendment Wednesday that gives Medicare Part D plans the authority to require at-risk beneficiaries to use a single prescriber and pharmacy for frequently abused drugs.
     
X
This ad will auto-close in 10 seconds